ArticleBiomedicines2024
Proposal and Definition of an Intelligent Clinical Decision Support System Applied to the Prediction of Dyspnea after 12 Months of an Acute Episode of COVID-19.
Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Characterization of Patients with Non-Small Cell Lung Cancer Using Machine Learning Tools: Relationship with Prognostic Biomarkers and Overall Survival-A Pilot Study.Journal of clinical medicine · 2026Article
- Development of an Intelligent Clinical Decision Support System for Predicting One-Year CPAP Adherence in Patients with Obstructive Sleep Apnea: A Pilot Study.Journal of clinical medicine · 2026Article
- Development of an Intelligent Clinical Decision Support System for Spirometry Quality Control.Diagnostics (Basel, Switzerland) · 2026Article
- Computer vision-based support system for B-line detection in lung ultrasound.Frontiers in digital health · 2026Article
- Artificial Intelligence Applications in Chronic Obstructive Pulmonary Disease: A Global Scoping Review of Diagnostic, Symptom-Based, and Outcome Prediction Approaches.Biomedicines · 2025Review
- Combined Applications of Artificial Intelligence and Simulation for Healthcare Process Optimization: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Predicting COPD Readmission: An Intelligent Clinical Decision Support System.Diagnostics (Basel, Switzerland) · 2025Article
- Impact of the COVID-19 infection on children with allergic diseases in China.Pediatric research · 2025Article
- Digital approaches in post-COVID healthcare: a systematic review of technological innovations in disease management.Biology methods & protocols · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long COVID is a condition that affects a significant proportion of patients who have had COVID-19. It is characterised by the persistence of associated symptoms after the acute phase of the illness has subsided. Although several studies have investigated the risk factors associated with long COVID, identifying which patients will experience long-term symptoms remains a complex task. Among the various symptoms, dyspnea is one of the most prominent due to its close association with the respiratory nature of COVID-19 and its disabling consequences. This work proposes a new intelligent clinical decision support system to predict dyspnea 12 months after a severe episode of COVID-19 based on the SeguiCovid database from the Álvaro Cunqueiro Hospital in Vigo (Galicia, Spain). The database is initially processed using a CART-type decision tree to identify the variables with the highest predictive power. Based on these variables, a cascade of expert systems has been defined with Mamdani-type fuzzy-inference engines. The rules for each system were generated using the Wang-Mendel automatic rule generation algorithm. At the output of the cascade, a risk indicator is obtained, which allows for the categorisation of patients into two groups: those with dyspnea and those without dyspnea at 12 months. This simplifies follow-up and the performance of studies aimed at those patients at risk. The system has produced satisfactory results in initial tests, supported by an AUC of 0.75, demonstrating the potential and usefulness of this tool in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.